Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants. Secondary Objective: To assess the tolerability and safety of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants
The duration of the study for a participant will be up to approximately 7 weeks and include: * Screening period: up to 4 weeks (Day -28 to Day -2). * Institutionalization period at each period of treatment: 4 days (Day -1 to Day 3, single SAR443820 administration on Day 1). * Wash-out period: at least 5 days between each dosing. * End-of-study visit: Period 3/ Day 6±1 day.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Capsule Oral
Investigational Site Number :8260001
Harrow, London, City of, United Kingdom
Assessment of pharmacokinetic (PK) parameter: Cmax
Maximum plasma concentration
Time frame: Up to day 3
Assessment of pharmacokinetic (PK) parameter: AUClast
Area under the plasma concentration versus time curve from time zero to the real time last
Time frame: Up to day 3
Assessment of pharmacokinetic (PK) parameter: AUC
Area under the plasma concentration versus time curve
Time frame: Up to day 3
Assessment of adverse events (AEs)
Number of participants with Adverse events
Time frame: Up to day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.